MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad's molecular residual disease assay
MWN-AI** Summary
The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. have announced a strategic alliance aimed at enhancing the clinical evaluation of Myriad's advanced molecular residual disease (MRD) assay, known as Precise MRD. This five-year collaboration seeks to leverage the expertise of MD Anderson in clinical and translational research alongside Myriad's proven strengths in oncology diagnostics.
The focus of this partnership is to create a series of studies that will assess the clinical validity and utility of the Precise MRD test, which is designed to detect tumor-derived DNA at exceptionally low levels, surpassing the capabilities of first-generation MRD tests. Dr. Dale Muzzey, Chief Scientific Officer at Myriad, expressed optimism regarding the potential for this technology to improve treatment strategies and patient outcomes by allowing for precise monitoring of therapy responses and recurrences.
Under the agreement, MD Anderson will spearhead patient enrollment, sample collection, data analysis, and manuscript preparation, while Myriad will provide funding, testing, and scientific support, in addition to potential milestone and royalty provisions. The studies will encompass various cancer types, including breast, gastrointestinal, genitourinary, and gynecological cancers, with the objective of generating evidence to support broader adoption of MRD testing in clinical practice.
Dr. Christopher Flowers of MD Anderson emphasized the alliance’s intent to explore multiple applications for MRD testing, such as identifying high-risk patients and monitoring for treatment relapse, ultimately enhancing cancer care and guiding clinical trial participation. This strategic collaboration builds on existing projects between the two organizations, reinforcing their commitment to advancing cancer research and treatment methodologies.
MWN-AI** Analysis
The recent announcement of a strategic alliance between Myriad Genetics and the University of Texas MD Anderson Cancer Center signals a pivotal development in the oncology diagnostics field. Spanning five years, this collaboration aims to accelerate the clinical evaluation of Myriad's molecular residual disease (MRD) assay, Precise MRD, enhancing cancer treatment protocols and monitoring mechanisms.
Investors in Myriad Genetics may find the collaboration particularly promising. MD Anderson's reputation as a leading cancer care facility lends credibility to the research efforts, potentially facilitating the assay’s integration into clinical practice. As both organizations leverage their strengths—MD Anderson’s expertise in clinical trials and Myriad’s innovative testing technology—the partnership is expected to yield a robust portfolio of studies across various cancer types, including breast, gastrointestinal, and gynecological cancers.
Given the increasing focus on personalized medicine, the ability of the Precise MRD test to detect tumor-derived DNA at low levels could not only improve treatment strategies but also significantly impact patient outcomes—a vital benchmark for healthcare providers. Successful outcomes from their studies could pave the way for inclusion in national guidelines, which would further drive adoption among oncologists and hospitals, thus enhancing Myriad's revenue prospects.
However, potential investors should remain cautious. The partnership entails certain risks, including the inherent uncertainties of clinical studies and the necessity of regulatory approvals. Additionally, Myriad's dependence on its technology’s validation and adoption underlines the importance of consistent communication about progress to stakeholders.
In conclusion, while the strategic alliance represents a strong case for growth, investors should balance optimism with an awareness of the complexities and potential volatility associated with biotech and diagnostic product commercialization. Continuous monitoring of study outcomes and their implications on market positioning will be crucial in assessing the long-term viability of this investment opportunity.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
HOUSTON and SALT LAKE CITY, Jan. 07, 2025 (GLOBE NEWSWIRE) -- The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc . today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad’s molecular residual disease (MRD) assay.
This strategic alliance brings together the longstanding oncology diagnostic experience of Myriad Genetics and the clinical and translational research expertise of MD Anderson to create a portfolio of studies to evaluate the clinical validity and utility of Myriad’s Precise MRD.
“We look forward to working with MD Anderson to evaluate Precise MRD’s utility in cancer care,” said Dale Muzzey, PhD, Chief Scientific Officer at Myriad Genetics. “Our collaborative studies will explore how our ultrasensitive Precise MRD test can enhance treatment strategies for providers and improve patient outcomes. We are optimistic that our MRD test’s ability to quantitatively detect tumor-derived DNA at very low levels — far lower than is possible with first-generation MRD tests — will open new opportunities for therapy-response and recurrence monitoring.”
Under the terms of the agreement, MD Anderson and Myriad Genetics will collaborate to design both retrospective and prospective studies to investigate the test’s utility in breast, gastrointestinal, genitourinary, and gynecological cancers. The goal of these studies is to generate evidence that supports national guideline inclusion and healthcare provider adoption. MD Anderson investigators will lead patient enrollment, sample collection, clinical data analysis and manuscript writing. Myriad will provide funding, MRD testing and scientific research support as well as potential milestone and royalty payments under the collaboration.
“This strategic alliance brings together cutting-edge technology and expertise from Myriad with disease-focused expertise and clinical trials excellence from MD Anderson,” said Christopher Flowers, M.D. , division head of Cancer Medicine at MD Anderson. “We aim to explore numerous applications for MRD testing, including monitoring patients for relapse after treatment, identifying high-risk patients in need of clinical trials, and potentially intervention approaches.”
The alliance expands upon existing collaborations between MD Anderson researchers and Myriad, including ongoing studies in breast cancer and renal cell carcinoma.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit Myriad.com .
About MD Anderson
The University of Texas MD Anderson Cancer Cente r in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world, and, in 1971, it became one of the nation’s first National Cancer Institute (NCI)-designated comprehensive cancer centers. MD Anderson is No. 1 for cancer in U.S. News & World Report’s “Best Hospitals” rankings and has been named one of the nation’s top two hospitals for cancer since the rankings began in 1990. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including that Myriad will work with MD Anderson to evaluate Precise MRD’s utility in cancer care, MD Anderson and Myriad Genetics will collaborate to design both retrospective and prospective studies to investigate the test’s utility in breast, gastrointestinal, genitourinary, and gynecological cancers, the collaborative studies will explore how the Precise MRD test can enhance treatment strategies for providers and improve patient outcomes, and Myriad’s belief that its MRD test’s ability to quantitatively detect tumor-derived DNA at very low levels will open new opportunities for therapy-response and recurrence monitoring. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com
FAQ**
How might the collaboration between MD Anderson and Myriad Genetics impact the financial performance of Blackrock MuniYield Fund Inc. (MYD), considering the potential innovations in cancer care and genetic testing?
In what ways could advancements from the MD Anderson-Myriad alliance influence the healthcare sector and, subsequently, the investment strategies of Blackrock MuniYield Fund Inc. (MYD)?
Can the outcomes of the retrospective and prospective studies on MRD testing by MD Anderson and Myriad Genetics affect the risk profile and performance expectations of Blackrock MuniYield Fund Inc. (MYD)?
How could successful integration of Myriad Genetics' MRD assay into clinical practice shape growth opportunities for funds like Blackrock MuniYield Fund Inc. (MYD) that invest in healthcare-related equities?
**MWN-AI FAQ is based on asking OpenAI questions about Blackrock MuniYield Fund Inc. (NYSE: MYD).
NASDAQ: MYD
MYD Trading
0.56% G/L:
$10.79 Last:
38,526 Volume:
$10.73 Open:
